Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mercanto HoldingsTGSHF 33 3-Year EBITDA Growth Rate is 37.00% as of Apr. 2026, which is at its 10-year median of 37.00. GuruFocus rates TGSHF with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 809 Drug Manufacturers companies, Mercanto Holdings ranks better than 83.93% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 37.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Mercanto Holdings was 37.00% per year. The lowest was 37.00% per year. And the median was 37.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Mercanto Holdings 3-Year EBITDA Growth Rate Related Terms
TGSHF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mercanto Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercanto Holdings 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercanto Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Mercanto Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 37.00% mean?
Mercanto Holdings (TGSHF) has a 3-Year EBITDA Growth Rate of 37.00% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mercanto Holdings and its competitors. This is near median its historical median of 37.00. Over the past decade, Mercanto Holdings' 3-Year EBITDA Growth Rate has ranged from 37.00 to 37.00. According to the industry distribution chart, Mercanto Holdings ranks #130 out of 809 companies in the Drug Manufacturers industry, placing it in the top 16.1%.
Is Mercanto Holdings' 3-Year EBITDA Growth Rate too high?
Mercanto Holdings' current 3-Year EBITDA Growth Rate of 37.00% is near median its 10-year median of 37.00. Over the past 10 years, this metric has ranged from a low of 37.00 to a high of 37.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Mercanto Holdings' value of 37.00% is 315.7% above this industry median. Based on the distribution chart, Mercanto Holdings ranks #130 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mercanto Holdings has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Mercanto Holdings' 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mercanto Holdings ranks #130 out of 809 companies for 3-Year EBITDA Growth Rate. This places Mercanto Holdings in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Mercanto Holdings' value of 37.00% is 315.7% above this benchmark. Historically, Mercanto Holdings' own 3-Year EBITDA Growth Rate has ranged from 37.00 to 37.00 over the past decade. While the company's 10-year median is 37.00 vs. the industry median of 8.90, Mercanto Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mercanto Holdings's current 3-Year EBITDA Growth Rate of 37.00% is 315.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Mercanto Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercanto Holdings's current 3-Year EBITDA Growth Rate is 37.00%, which is near median its own 10-year median of 37.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercanto Holdings stock overvalued right now?
Mercanto Holdings (TGSHF) has a current 3-Year EBITDA Growth Rate of 37.00%. The current 3-Year EBITDA Growth Rate is 37.00%, which is near median its 10-year median of 37.00 and 315.7% above the Drug Manufacturers industry median of 8.90. Mercanto Holdings' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Mercanto Holdings (TGSHF), the current 3-Year EBITDA Growth Rate is 37.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mercanto Holdings Inc operates a portfolio of brands that include traditional cannabis and beverage products. The company exists to promote the use of mushrooms through its brands; The company offers quality products that promote health, recreation, and well-being. The portfolio of the company includes different cannabis products, probiotic, functional mushroom beverages, and others.
33GF Score
Get the complete analysis for TGSHF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGSHF has been successfully added to your 
